SHIP cluster U-turns on Lucentis policy after price is slashed
A primary care trust cluster under the threat of legal action for recommending the use of an unlicensed drug has revoked the policy after the pharmaceutical company cut the price of the medicine.
Continue reading this article – simply subscribe below
Subscribe now for instant access to hsj.co.uk and our mobile site. Choose the package that suits you and get the weekly magazine, iPad app or both.
If you are a Health Service Journal subscriber please sign in with your email address and click submit: